Fiche du document
2016
- doi: 10.4414/smw.2016.14322
- issn: 0036-7672
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.4414/smw.2016.14322
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/27346233
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1424-3997
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_CFDB8F8346676
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Osteopsathyrosis Osteogenesis imperfecta congenita Osteogenesis imperfecta tarda Lobstein's disease Fragilitas ossium Brittle bones Bone development Osteogenesis Bone growth Bone--GrowthCiter ce document
A. Bregou Bourgeois et al., « Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives. », Serveur académique Lausannois, ID : 10.4414/smw.2016.14322
Métriques
Partage / Export
Résumé
Osteogenesis imperfecta is an inherited connective tissue disorder with wide phenotypic and molecular heterogeneity. A common issue associated with the molecular abnormality is a disturbance in bone matrix synthesis and homeostasis inducing bone fragility. In very early life, this can lead to multiple fractures and progressive bone deformities, including long bone bowing and scoliosis. Multidisciplinary management improves quality of life for patients with osteogenesis imperfecta. It consists of physical therapy, medical treatment and orthopaedic surgery as necessary. Medical treatment consists of bone-remodelling drug therapy. Bisphosphonates are widely used in the treatment of moderate to severe osteogenesis imperfecta, from infancy to adulthood. Other more recent drug therapies include teriparatide and denosumab. All these therapies target the symptoms and have effects on the mechanical properties of bone due to modification of bone remodelling, therefore influencing skeletal outcome and orthopaedic surgery. Innovative therapies, such as progenitor and mesenchymal stem cell transplantation, targeting the specific altered pathway rather than the symptoms, are in the process of development.